# Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Study · id `cardio:ct-nct03385239` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03385239](<https://clinicaltrials.gov/study/NCT03385239>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03385239

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

## Technical summary

Registry record NCT03385239. Randomized; triple masking; primary purpose treatment. Start 2018-01-30 (actual); primary completion 2019-11-25 (actual). Results posted on 2023-01-11.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 114 participants (enrolled count; ClinicalTrials.gov record NCT03385239, source copy `cardio:ctgov-nct03385239-2023-01-11`, retrieved 2026-10-31)
- Started: 2018-01-30 (actual) (ClinicalTrials.gov record NCT03385239, source copy `cardio:ctgov-nct03385239-2023-01-11`, retrieved 2026-10-31)
- Primary completion: 2019-11-25 (actual) (ClinicalTrials.gov record NCT03385239, source copy `cardio:ctgov-nct03385239-2023-01-11`, retrieved 2026-10-31)
- Completion: 2020-02-25 (actual) (ClinicalTrials.gov record NCT03385239, source copy `cardio:ctgov-nct03385239-2023-01-11`, retrieved 2026-10-31)
- Results first posted: 2023-01-11 (ClinicalTrials.gov record NCT03385239, source copy `cardio:ctgov-nct03385239-2023-01-11`, retrieved 2026-10-31)
- Countries: United States; Canada (ClinicalTrials.gov record NCT03385239, source copy `cardio:ctgov-nct03385239-2023-01-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03385239-2023-01-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
- Condition: Hypertriglyceridemia
- Condition: Cardiovascular Diseases
- Intervention (Drug): ISIS 678354
- Intervention (Drug): Placebo
- Lead sponsor: Akcea Therapeutics
- Lead sponsor class: INDUSTRY
- Collaborator: Ionis Pharmaceuticals, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Akcea Therapeutics (`cardio:org-akcea-therapeutics`)
- Registry lists this organization as a collaborator: Ionis Pharmaceuticals, Inc. (`cardio:org-ionis-pharmaceuticals-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk (`cardio:pubmed-35025993`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 11747eda912ee33b2cd0003dc6b10f87db2da90ac72969a4275ae6b018142bc8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
